Literature DB >> 9492032

Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells.

J Rubin1, D M Biskobing, L Jadhav, D Fan, M S Nanes, S Perkins, X Fan.   

Abstract

The mechanisms by which glucocorticosteroids promote osteoclastogenesis in vitro are uncertain. As macrophage colony-stimulating factor (MCSF) is critical for osteoclastogenesis, we hypothesized that glucocorticosteroids might regulate membrane-bound MCSF (mMCSF) and soluble MCSF (sMCSF) production by stromal cells or osteoblasts. ST2 cells or murine calvarial osteoblasts (MOBs) were treated with dexamethasone (Dex; 100 nM) and/or 1,25-dihydroxyvitamin D [1,25(OH)2D; 10 nM] for 3 days. Control values for mMCSF and sMCSF as units per 100,000 cells were 9 +/- 1.4 and 511 +/- 56 in ST2 cells and 5.9 +/- 0.8 and 379 +/- 47 in MOB cells, respectively. Dex increased mMCSF to 156 +/- 16% and 143 +/- 26% compared with the control value in ST2 and MOB cells, respectively, whereas 1,25-(OH)2D caused increases of 195 +/- 16% and 164 +/- 21%. In the presence of both Dex and 1,25-(OH)2D, mMCSF increased to 209 +/- 24% and 216 +/- 26% in the two cell types, respectively. 1,25-(OH)2D caused modest increases in sMCSF, as expected, in both cell types (153 +/- 6% and 122 +/- 4%). Dex inhibited 1,25-(OH)2D-stimulated sMCSF (115 +/- 7% of control) in ST2 cells. Analysis of mMCSF transcript levels by semiquantitative RT-PCR revealed Dex-stimulated increases of 170 +/- 11% in ST2 cells and 126 +/- 16% in MOB cells compared with the control level. The increased expression of the transcript for sMCSF in the presence of Dex and 1,25-(OH)2D, measured by both RT-PCR and Northern analysis (219 +/- 53% and 242%, respectively), despite inhibition of sMCSF protein, indicated that the inhibitory effect of Dex in ST2 cells was posttranscriptional. Half-life studies showed that Dex prolonged MCSF messenger RNA from 2.8 to 7.5 h. These results suggest that Dex influences osteoclastogenesis by increasing the expression of mMCSF by accessory cells in culture.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9492032     DOI: 10.1210/endo.139.3.5778

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  23 in total

1.  Bone turnover markers, BMD and TBS after short-term, high-dose glucocorticoid therapy in patients with Graves' orbitopathy: a small prospective pilot study.

Authors:  S Censi; J Manso; G Pandolfo; G Franceschet; E Cavedon; Y H Zhu; S Carducci; W Gomiero; M Plebani; M Zaninotto; S Watutantrige-Fernando; C Mian; V Camozzi
Journal:  J Endocrinol Invest       Date:  2018-12-05       Impact factor: 4.256

Review 2.  Psychological stress and aging: role of glucocorticoids (GCs).

Authors:  K M Mehedi Hasan; Md Shaifur Rahman; K M T Arif; Mahbub E Sobhani
Journal:  Age (Dordr)       Date:  2011-10-05

Review 3.  Endogenous Glucocorticoids and Bone.

Authors:  Hong Zhou; Mark S Cooper; Markus J Seibel
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

Review 4.  Mechanisms of glucocorticoid action in bone.

Authors:  Ernesto Canalis
Journal:  Curr Osteoporos Rep       Date:  2005-09       Impact factor: 5.096

Review 5.  Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros.

Authors:  Maurizio Rossini; Giovanni Orsolini; Ombretta Viapiana; Silvano Adami; Davide Gatti
Journal:  Endocrine       Date:  2015-02-04       Impact factor: 3.633

6.  Glucocorticoids suppress bone formation via the osteoclast.

Authors:  Hyun-Ju Kim; Haibo Zhao; Hideki Kitaura; Sandip Bhattacharyya; Judson A Brewer; Louis J Muglia; F Patrick Ross; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2006-07-27       Impact factor: 14.808

Review 7.  Management of glucocorticoid-induced osteoporosis.

Authors:  Juliet Compston
Journal:  Nat Rev Rheumatol       Date:  2010-02       Impact factor: 20.543

Review 8.  Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment.

Authors:  Pojchong Chotiyarnwong; Eugene V McCloskey
Journal:  Nat Rev Endocrinol       Date:  2020-04-14       Impact factor: 43.330

9.  Glycyrrhizic acid (GCA) as 11β-hydroxysteroid dehydrogenase inhibitor exerts protective effect against glucocorticoid-induced osteoporosis.

Authors:  Elvy Suhana Mohd Ramli; Farihah Suhaimi; Siti Fadziyah Mohamad Asri; Fairus Ahmad; Ima Nirwana Soelaiman
Journal:  J Bone Miner Metab       Date:  2012-12-30       Impact factor: 2.626

Review 10.  Adrenocortical incidentalomas and bone: from molecular insights to clinical perspectives.

Authors:  Barbara Altieri; Giovanna Muscogiuri; Stavroula A Paschou; Andromachi Vryonidou; Silvia Della Casa; Alfredo Pontecorvi; Martin Fassnacht; Cristina L Ronchi; John Newell-Price
Journal:  Endocrine       Date:  2018-08-02       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.